Arecor Therapeutics PLC (GB:AREC) has released an update.
Arecor Therapeutics PLC has announced the successful Phase 1 clinical trial results for AT278, an innovative ultra-concentrated and ultra-rapid acting insulin, and will present the data at the European Association for the Study of Diabetes 2024. The study indicates AT278’s potential as a first-of-its-kind treatment for overweight and obese individuals with type 2 diabetes, offering a significant advancement in insulin therapy. The company aims to address the needs of patients with high daily insulin requirements through this pioneering product.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.
